Flash Finance

GlaxoSmithKline Pharmaceuticals LimitedGLAXOCorporate

Healthcare Drug Manufacturers - General Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹2,566.10
MCap ₹43,471 Cr · P/E 40.7
GlaxoSmithKline Pharmaceuticals Limited — Stock analysis & AI research GlaxoSmithKline Pharmaceuticals Limited — Seasonality — best & worst months GlaxoSmithKline Pharmaceuticals Limited — Technical indicators & charts GlaxoSmithKline Pharmaceuticals Limited — Technical setup — score, trend, support & resistance GlaxoSmithKline Pharmaceuticals Limited — Live exchange announcements
📋 High ROE Stocks📋 High ROCE Stocks📋 High Operating Margin Stocks📋 High Interest Coverage Stocks📋 Stocks Cheaper Than Their Industry📋 Low Debt Stocks ⚖️ vs Abbott India⚖️ vs Pfizer 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹938 Cr
Sales · Jun 2026
+16.6% YoY
₹296 Cr
Operating Profit · Jun 2026
+17.6% YoY
31.5%
OPM % · Jun 2026
+1.0% YoY
₹237 Cr
Net Profit · Jun 2026
+15.7% YoY
—
EPS · Jun 2026

📝 GlaxoSmithKline Pharmaceuticals Limited — results explained

Quarter ended June 2026 (Q1 FY27)

GlaxoSmithKline Pharmaceuticals Limited reported revenue of ₹938 crore for the quarter ended June 2026 (Q1 FY27), up 16.6% from ₹805 crore in the same quarter last year, and down 5.7% sequentially over the March 2026 quarter.

Net profit rose 15.7% year-on-year to ₹237 crore, from ₹205 crore.

Operating profit stood at ₹296 crore — an operating margin (OPM) of 31.5%, compared with 31.2% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, GlaxoSmithKline Pharmaceuticals Limited posted revenue of ₹3,821 crore, a growth of 1.9% over FY25, with a net profit of ₹1,036 crore (up 11.6% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹3,955 crore with a net profit of ₹1,068 crore.

Valuation snapshot

At the current price of ₹2,566.10, GLAXO has a market capitalisation of ₹43,471 crore and a trailing P/E of about 40.7.

Within the Drug Manufacturers - General industry, it is the largest of the 5 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 75.00%, foreign institutional investors (FIIs) 4.75%, domestic institutional investors (DIIs) 8.48%, public shareholders 11.77% of GlaxoSmithKline Pharmaceuticals Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹43,471 Cr
Current Price ?
₹2,566.1
P/E ?
40.71below ind
Industry P/E ?
62.30
P/B ?
19.18
P/S ?
10.99
P/FCF ?
49.97
Enterprise Value ?
₹43,504 Cr
EV/EBITDA ?
26.96
PEG ?
2.26
Earnings Yield ?
3.5%
Dividend Yield ?
2.24%
Profitability & Returns
Sales (TTM) ?
₹3,955 Cr
OPM ?
40.8%
Profit after tax (TTM) ?
₹1,068 Cr
EPS (TTM) ?
₹63.03
ROCE ?
61.0%
ROE ?
47.1%
ROA ?
24.7%
Growth
Sales — latest qtr ?
₹938 Cr
PAT — latest qtr ?
₹237 Cr
YoY qtr sales growth ?
16.6%
YoY qtr profit growth ?
15.7%
Sales growth (3y) ?
6%
Sales growth (5y) ?
5%
Profit growth (3y) ?
18%
Profit growth (5y) ?
15%
Financial Health
Debt ?
₹33 Cr
Debt to Equity ?
0.01
Interest Coverage ?
420.2
Current Ratio ?
N/A
Ownership
Promoter holding ?
75.00%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
4.5%
Return 6 months ?
4.6%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 8027877629578059308151,0119499748059801,041995938 +16.6% -5.7%
Operating Profit 229170144289218257231322292333251596371351296 +17.6% -15.8%
Other Income 232836282830363535414468323644 +0.1% +21.6%
Interest 010001000101111 +131.0% -3.0%
Depreciation 161716181718161719151633201316 +2.1% +21.8%
Profit Before Tax 22419018129965271249344308359279633400373322 +15.6% -13.6%
Net Profit 16513313221846194182252230263205257296278237 +15.7% -14.7%
EPS 9.717.887.8112.842.7011.4810.7614.9113.5715.5212.1015.2017.4516.40— — —
OPM % 28.5% 21.6% 18.9% 30.3% 27.1% 27.7% 28.3% 31.8% 30.7% 34.2% 31.2% 60.8% 35.7% 35.3% 31.5% +1.0% -10.8%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹3,749 Cr ₹3,821 Cr ₹3,955 Cr +1.9%
Operating Profit ₹1,177 Cr ₹1,569 Cr ₹1,614 Cr +33.3%
OPM % 31.40% 41.06% 40.80% +30.8%
NPM % 24.74% 27.10% 27.00% +9.5%
Other Income ₹146 Cr ₹180 Cr ₹180 Cr +23.6%
Depreciation ₹67 Cr ₹82 Cr ₹82 Cr +22.5%
Interest ₹1 Cr ₹4 Cr ₹4 Cr +170.2%
EBIT ₹1,111 Cr ₹1,487 Cr ₹1,531 Cr +33.9%
PBT ₹1,260 Cr ₹1,685 Cr ₹1,728 Cr +33.7%
Tax ₹332 Cr ₹178 Cr ₹190 Cr -46.3%
Net Profit ₹928 Cr ₹1,036 Cr ₹1,068 Cr +11.6%
EPS ₹54.76 ₹61.15 ₹49.05 +11.7%
Material Cost ₹1,345 Cr ₹657 Cr ₹749 Cr -51.1%
Employee Cost ₹580 Cr ₹304 Cr ₹311 Cr -47.5%
Extraordinary Items ₹5 Cr ₹21 Cr ₹21 Cr +339.7%

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 169169169169 +0.0%
Reserves 1,5721,6081,7822,098 +17.7%
Borrowings 16191033 +230.0%
Other Liabilities 1,5701,7602,1472,023 -5.8%
Total Liabilities 3,3273,5574,1084,324 +5.3%
Fixed Assets 330321284281 -1.1%
CWIP 20141433 +135.7%
Investments 5188131,1181,392 +24.5%
Other Assets 2,4582,4082,6922,618 -2.7%
Total Assets 3,3273,5574,1084,324 +5.3%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 4845821,290903 -30.0%
Cash from Investing Activity 8089-46397 +963.0%
Cash from Financing Activity -1,543-562-769-737 +4.2%
Net Cash Flow -25129475563 +18.5%
Free Cash Flow 4515731,273870 -31.7%
CFO/OP 93%92%116%93% -19.8%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 22232826 -7.1%
Inventory Days 131144126124 -1.6%
Days Payable 122171186154 -17.2%
Cash Conversion Cycle 31-4-31-4 +87.1%
Working Capital Days -57-64-99-91 +8.1%
ROCE % 36%51%63%61% -3.2%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 75.00%75.00%75.00%75.00%75.00% +0.0%
FIIs 4.89%4.79%4.63%4.62%4.75% +2.8%
DIIs 7.71%7.75%7.70%7.68%8.48% +10.4%
Government 0.00%0.00%0.00%0.00%— —
Public 12.41%12.45%12.67%12.69%11.77% -7.2%
No. of Shareholders 1,23,6291,22,9041,22,4601,21,7631,19,337 -2.0%

⚖️ Peer comparison

Industry: Drug Manufacturers - General · 5 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 GLAXO GlaxoSmithKline Pharmaceuticals ₹2,818.90 47,754 44.7 3,955 1,068 40.8% 27.0% 1.9% 11.6% 16.6% 15.7%
2 RUBICON RUBICON RESEARCH ₹1,839.40 30,367 103.7 1,936 288 23.3% 14.9% — — 51.8% 97.2%
3 PFIZER Pfizer ₹4,055.00 18,551 25.2 2,569 735 36.7% 28.6% 10.4% -5.8% 8.3% 6.2%
4 SAIPARENT Sai Parenterals ₹498.00 2,200 — — — — — — — 435.1% 458.0%
5 SYMBIOTEC Symbiotec Pharmalab ₹1,107.00 — — — — — — — — 7.5% -53.1%
❓ Frequently asked questions
What was GlaxoSmithKline Pharmaceuticals Limited's revenue in Q1 FY27?
GlaxoSmithKline Pharmaceuticals Limited reported revenue of ₹938 crore for the quarter ended June 2026 (Q1 FY27), up 16.6% from ₹805 crore in the same quarter last year, and down 5.7% sequentially over the March 2026 quarter.
What was GlaxoSmithKline Pharmaceuticals Limited's net profit in Q1 FY27?
Net profit rose 15.7% year-on-year to ₹237 crore, from ₹205 crore.
What is GLAXO's market capitalisation and P/E ratio?
At the current price of ₹2,566.10, GLAXO has a market capitalisation of ₹43,471 crore and a trailing P/E of about 40.7.
Who owns GlaxoSmithKline Pharmaceuticals Limited? (shareholding pattern)
As of Sep 2026, promoters held 75.00%, foreign institutional investors (FIIs) 4.75%, domestic institutional investors (DIIs) 8.48%, public shareholders 11.77% of GlaxoSmithKline Pharmaceuticals Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI